search
Back to results

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
LY2963016
Lantus®
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Insulin glargine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have T2DM based on the disease diagnostic criteria World Health Organization (WHO) classification.
  • Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to screening.
  • Have a HbA1c ≥7.0% and ≤11.0%.
  • Body mass index (BMI) ≤35 kilograms per meter squared.

Exclusion Criteria:

  • Have used insulin therapy (outside of pregnancy) anytime in the past 1 year, except for short-term treatment of acute conditions, and up to a maximum of 4 continuous weeks.
  • Have used any glucagon like peptide (GLP-1) receptor agonists within the previous 90 days.
  • Are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening.
  • Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.
  • Have had ≥2 emergency room visits or hospitalizations due to poor glucose control.
  • Have known hypersensitivity or allergy to Lantus® or its excipients.
  • Are receiving chronic systemic glucocorticoid therapy at pharmacological doses or have received such therapy within 4 weeks immediately preceding screening.
  • Have obvious signs or symptoms, or laboratory evidence, of liver disease.
  • Have one of the following concomitant diseases: significant cardiac or gastrointestinal disease.
  • Have a history of renal transplantation, are currently receiving renal dialysis or have a serum creatinine greater than 2.0 milligrams per deciliter.
  • Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.
  • Participants with active cancer or personal history of cancer within the previous 5 years.
  • Are pregnant or intend to become pregnant during the course of the study.
  • Are women who are breastfeeding.

Sites / Locations

  • Anhui Provincial Hospital
  • The First Affiliated Hospital of Lanzhou University
  • Shantou University Medical College No.2 Affiliated Hospital
  • Guangdong Province People's Hospital
  • The First Affiliated Hospital, Sun-Yat Sen University
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
  • The 1st Affiliated Hospital of Henan Science and technology
  • Tongji Hosp Tongji Med Col Huazhong Univ of Sci & Tech
  • Wuhan Central Hospital
  • The First People Hospital of Yueyang
  • Changzhou No.2 People's Hospital
  • The Affliated Jiangyin Hospital of Southeast University Medical College
  • Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med
  • The Second Affiliated Hospital of Nanjing Medical University
  • Nanjing First Hospital
  • Nanjing Jiangning Hospital
  • Wuxi People's Hospital
  • Xuzhou central Hospital
  • Affiliated Hospital of Jiangsu University
  • No.2 Hospital Affiliated to Jilin University
  • Siping central people's hospital
  • Dalian Med. Univ. No 2 Affiliate Hospital
  • Shengjing Hospital of China Medical University
  • The First Affiliated Hospital with Nanjing Medical Universit
  • General Hospital of Ningxia Medical University
  • 1st affiliated Hospital of Shanxi Medical University
  • Jinan Central Hospital
  • West China Hospital of Sichuan University
  • Peking Union Medical College Hospital
  • Chongqing General Hospital
  • Shanghai Putuo District Center Hospital
  • Tianjin Medical University General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

LY2963016

Lantus®

Arm Description

Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre [mmol/L]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).

Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.

Outcomes

Primary Outcome Measures

Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated by mixed-effects model for repeated measures (MMRM) with baseline, insulin secretagogues at study entry, treatment, visit and treatment*visit in the model.

Secondary Outcome Measures

Change From Baseline in HbA1c (Lantus® to LY2963016)
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, treatment, visit and treatment*visit in the model.
Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, 2 Hours After Evening Meal and Bed Time. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Percentage of Participants With HbA1c <7% at Week 24
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Percentage of Participants With HbA1c ≤6.5% at Week 24
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Change From Baseline in Glycemic Variability of Fasting Blood Glucose
Glycemic variability is measured by the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning and daily pre-meal blood glucose value from the 7-point self-monitoring blood glucose [SMBG] profiles. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Basal Insulin Dose Units Per Day
Units of basal insulin dose taken per day (U/day). LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Change From Baseline in Basal Insulin Dose Units Per Day
Units of basal insulin dose taken per day (U/day). LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Change From Baseline in Body Weight
Change from baseline in body weight was evaluated. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Insulin Treatment Satisfaction Questionnaire (ITSQ)
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen [(IR) 5 items: domain scores range (DSR) 5-35], Lifestyle Flexibility [(LF) 3 items: DSR 3-21], Glycemic Control [(GC) 3 items: DSR 3-21], Hypoglycemic Control [(HC) 5 items: DSR 5-35], Insulin Delivery Device [(IDD) 6 items: DSR 6-42]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100*[(7-mean raw score)/6]. Higher scores indicate better treatment satisfaction. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Number of Participants With Detectable Anti-Glargine Antibodies
Number of participants with detectable anti-glargine antibodies were reported.
Rate of Total Symptomatic and Nocturnal Hypoglycemia Events (Adjusted by 1 Year)
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a negative-binomial regression model with treatment as fixed effects and log of (participant's treatment duration/365.25) as an offset variable. A nocturnal hypoglycemic event is defined as any total hypoglycemia event that occurred between bedtime and waking.

Full Information

First Posted
November 7, 2017
Last Updated
May 3, 2021
Sponsor
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT03338010
Brief Title
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
Official Title
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
March 22, 2018 (Actual)
Primary Completion Date
March 18, 2020 (Actual)
Study Completion Date
March 18, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications (OAMs). Participants will continue their OAMs throughout the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Insulin glargine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
536 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LY2963016
Arm Type
Experimental
Arm Description
Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre [mmol/L]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).
Arm Title
Lantus®
Arm Type
Active Comparator
Arm Description
Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.
Intervention Type
Drug
Intervention Name(s)
LY2963016
Intervention Description
Administered SC
Intervention Type
Drug
Intervention Name(s)
Lantus®
Intervention Description
Administered SC
Primary Outcome Measure Information:
Title
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®)
Description
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated by mixed-effects model for repeated measures (MMRM) with baseline, insulin secretagogues at study entry, treatment, visit and treatment*visit in the model.
Time Frame
Baseline, Week 24
Secondary Outcome Measure Information:
Title
Change From Baseline in HbA1c (Lantus® to LY2963016)
Description
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, treatment, visit and treatment*visit in the model.
Time Frame
Baseline, Week 24
Title
Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
Description
Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, 2 Hours After Evening Meal and Bed Time. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Time Frame
Baseline, Week 24
Title
Percentage of Participants With HbA1c <7% at Week 24
Description
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Time Frame
Week 24
Title
Percentage of Participants With HbA1c ≤6.5% at Week 24
Description
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Time Frame
Week 24
Title
Change From Baseline in Glycemic Variability of Fasting Blood Glucose
Description
Glycemic variability is measured by the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning and daily pre-meal blood glucose value from the 7-point self-monitoring blood glucose [SMBG] profiles. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Time Frame
Baseline, Week 24
Title
Basal Insulin Dose Units Per Day
Description
Units of basal insulin dose taken per day (U/day). LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Time Frame
At Week 24
Title
Change From Baseline in Basal Insulin Dose Units Per Day
Description
Units of basal insulin dose taken per day (U/day). LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Time Frame
Baseline, Week 24
Title
Change From Baseline in Body Weight
Description
Change from baseline in body weight was evaluated. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Time Frame
Baseline, Week 24
Title
Insulin Treatment Satisfaction Questionnaire (ITSQ)
Description
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen [(IR) 5 items: domain scores range (DSR) 5-35], Lifestyle Flexibility [(LF) 3 items: DSR 3-21], Glycemic Control [(GC) 3 items: DSR 3-21], Hypoglycemic Control [(HC) 5 items: DSR 5-35], Insulin Delivery Device [(IDD) 6 items: DSR 6-42]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100*[(7-mean raw score)/6]. Higher scores indicate better treatment satisfaction. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment*time in the model.
Time Frame
At Week 24
Title
Number of Participants With Detectable Anti-Glargine Antibodies
Description
Number of participants with detectable anti-glargine antibodies were reported.
Time Frame
Baseline through 24 weeks
Title
Rate of Total Symptomatic and Nocturnal Hypoglycemia Events (Adjusted by 1 Year)
Description
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a negative-binomial regression model with treatment as fixed effects and log of (participant's treatment duration/365.25) as an offset variable. A nocturnal hypoglycemic event is defined as any total hypoglycemia event that occurred between bedtime and waking.
Time Frame
Baseline through 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have T2DM based on the disease diagnostic criteria World Health Organization (WHO) classification. Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to screening. Have a HbA1c ≥7.0% and ≤11.0%. Body mass index (BMI) ≤35 kilograms per meter squared. Exclusion Criteria: Have used insulin therapy (outside of pregnancy) anytime in the past 1 year, except for short-term treatment of acute conditions, and up to a maximum of 4 continuous weeks. Have used any glucagon like peptide (GLP-1) receptor agonists within the previous 90 days. Are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening. Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study. Have had ≥2 emergency room visits or hospitalizations due to poor glucose control. Have known hypersensitivity or allergy to Lantus® or its excipients. Are receiving chronic systemic glucocorticoid therapy at pharmacological doses or have received such therapy within 4 weeks immediately preceding screening. Have obvious signs or symptoms, or laboratory evidence, of liver disease. Have one of the following concomitant diseases: significant cardiac or gastrointestinal disease. Have a history of renal transplantation, are currently receiving renal dialysis or have a serum creatinine greater than 2.0 milligrams per deciliter. Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia. Participants with active cancer or personal history of cancer within the previous 5 years. Are pregnant or intend to become pregnant during the course of the study. Are women who are breastfeeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Anhui Provincial Hospital
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230001
Country
China
Facility Name
The First Affiliated Hospital of Lanzhou University
City
Lanzhou
State/Province
Gansu
ZIP/Postal Code
730000
Country
China
Facility Name
Shantou University Medical College No.2 Affiliated Hospital
City
Shantou
State/Province
Guang Dong Province
ZIP/Postal Code
515041
Country
China
Facility Name
Guangdong Province People's Hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Facility Name
The First Affiliated Hospital, Sun-Yat Sen University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Facility Name
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510120
Country
China
Facility Name
The 1st Affiliated Hospital of Henan Science and technology
City
Luoyang
State/Province
Henan
ZIP/Postal Code
471003
Country
China
Facility Name
Tongji Hosp Tongji Med Col Huazhong Univ of Sci & Tech
City
Wu Han
State/Province
Hubei
ZIP/Postal Code
430030
Country
China
Facility Name
Wuhan Central Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430014
Country
China
Facility Name
The First People Hospital of Yueyang
City
Yueyang
State/Province
Hunan
ZIP/Postal Code
414000
Country
China
Facility Name
Changzhou No.2 People's Hospital
City
Changzhou
State/Province
Jiangsu
ZIP/Postal Code
213003
Country
China
Facility Name
The Affliated Jiangyin Hospital of Southeast University Medical College
City
Jiangyin
State/Province
Jiangsu
ZIP/Postal Code
214400
Country
China
Facility Name
Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
Facility Name
The Second Affiliated Hospital of Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210011
Country
China
Facility Name
Nanjing First Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210012
Country
China
Facility Name
Nanjing Jiangning Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
211199
Country
China
Facility Name
Wuxi People's Hospital
City
Wuxi
State/Province
Jiangsu
ZIP/Postal Code
214023
Country
China
Facility Name
Xuzhou central Hospital
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221009
Country
China
Facility Name
Affiliated Hospital of Jiangsu University
City
Zhenjiang
State/Province
Jiangsu
ZIP/Postal Code
212001
Country
China
Facility Name
No.2 Hospital Affiliated to Jilin University
City
Changchun City
State/Province
Jilin
ZIP/Postal Code
130041
Country
China
Facility Name
Siping central people's hospital
City
Siping
State/Province
Jilin
ZIP/Postal Code
136000
Country
China
Facility Name
Dalian Med. Univ. No 2 Affiliate Hospital
City
Dalian
State/Province
Liao Ning
ZIP/Postal Code
116023
Country
China
Facility Name
Shengjing Hospital of China Medical University
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110022
Country
China
Facility Name
The First Affiliated Hospital with Nanjing Medical Universit
City
Nanjing
State/Province
Nanjing
ZIP/Postal Code
210029
Country
China
Facility Name
General Hospital of Ningxia Medical University
City
Yinchuan
State/Province
Ningxia
ZIP/Postal Code
750004
Country
China
Facility Name
1st affiliated Hospital of Shanxi Medical University
City
Tai Yuan
State/Province
Shan XI
ZIP/Postal Code
030001
Country
China
Facility Name
Jinan Central Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250013
Country
China
Facility Name
West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Facility Name
Peking Union Medical College Hospital
City
Beijing
ZIP/Postal Code
88798
Country
China
Facility Name
Chongqing General Hospital
City
Chongqing
ZIP/Postal Code
400013
Country
China
Facility Name
Shanghai Putuo District Center Hospital
City
Shanghai
ZIP/Postal Code
200062
Country
China
Facility Name
Tianjin Medical University General Hospital
City
Tianjin
ZIP/Postal Code
300052
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing URL
https://vivli.org/

Learn more about this trial

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs